{"nctId":"NCT00688870","briefTitle":"Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered to Infants in Taiwan","startDateStruct":{"date":"2008-06-05","type":"ACTUAL"},"conditions":["Vaccines","Pneumococcal Conjugate Vaccine"],"count":168,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Biological: 13-valent pneumococcal conjugate vaccine (13vPnC)"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: 7-valent pneumococcal conjugate vaccine (7vPnC)"]}],"interventions":[{"name":"13-valent pneumococcal conjugate vaccine (13vPnC)","otherNames":[]},{"name":"7-valent pneumococcal conjugate vaccine (7vPnC)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy 2-month-old infants (42 to 98 days)\n* Available for the entire study period (14 months)\n\nExclusion Criteria:\n\n* Previous vaccination with pneumococcal, diphtheria, tetanus, pertussis, polio, or Hib vaccines\n* A previous anaphylactic reaction to any vaccine or vaccine-related component.","healthyVolunteers":false,"sex":"ALL","minimumAge":"42 Days","maximumAge":"98 Days","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving a Predefined Antibody Level of Greater Than or Equal to 0.35 Micrograms (mcg)/mL, 1 Month After the Infant Series.","description":"Percentage of participants achieving a predefined antibody level of greater than or equal to 0.35 mcg/mL along with the corresponding exact 95% confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.8","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.8","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.8","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.8","spread":null},{"groupId":"OG001","value":"2.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.5","spread":null},{"groupId":"OG001","value":"2.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.8","spread":null},{"groupId":"OG001","value":"61.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"77.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"2.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a Predefined Antibody Level of Greater Than or Equal to 0.35 mcg/mL, 1 Month After the Toddler Dose","description":"Percentage of participants achieving a predefined antibody level of greater than or equal to 0.35 mcg/mL along with the corresponding exact 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"5.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.2","spread":null},{"groupId":"OG001","value":"13.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"90.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"6.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"98.8","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody, 1 Month After the Infant Series","description":"Antibody GMC as measured in mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.89","spread":null},{"groupId":"OG001","value":"4.64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.37","spread":null},{"groupId":"OG001","value":"4.82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.97","spread":null},{"groupId":"OG001","value":"2.92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.76","spread":null},{"groupId":"OG001","value":"11.59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.39","spread":null},{"groupId":"OG001","value":"3.07","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.60","spread":null},{"groupId":"OG001","value":"4.77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.93","spread":null},{"groupId":"OG001","value":"3.25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.14","spread":null},{"groupId":"OG001","value":"0.02","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.20","spread":null},{"groupId":"OG001","value":"0.05","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.47","spread":null},{"groupId":"OG001","value":"0.43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.57","spread":null},{"groupId":"OG001","value":"0.79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.67","spread":null},{"groupId":"OG001","value":"0.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.69","spread":null},{"groupId":"OG001","value":"2.46","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"GMC for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody, 1 Month After the Toddler Dose","description":"Antibody GMC as measured in mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.06","spread":null},{"groupId":"OG001","value":"6.34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.62","spread":null},{"groupId":"OG001","value":"13.28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.18","spread":null},{"groupId":"OG001","value":"3.88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.17","spread":null},{"groupId":"OG001","value":"12.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.67","spread":null},{"groupId":"OG001","value":"4.87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.07","spread":null},{"groupId":"OG001","value":"7.41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.51","spread":null},{"groupId":"OG001","value":"7.97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.62","spread":null},{"groupId":"OG001","value":"0.03","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.29","spread":null},{"groupId":"OG001","value":"0.12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.57","spread":null},{"groupId":"OG001","value":"0.95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.55","spread":null},{"groupId":"OG001","value":"3.79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.91","spread":null},{"groupId":"OG001","value":"0.06","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.82","spread":null},{"groupId":"OG001","value":"1.98","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Pre-specified Local Reactions: Infant Series Dose 1 (2 Months of Age).","description":"Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling and redness present); Mild (0.5 to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\\> 7.0 cm). Participants may be represented in more than 1 category.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.3","spread":null},{"groupId":"OG001","value":"34.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":null},{"groupId":"OG001","value":"9.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.6","spread":null},{"groupId":"OG001","value":"11.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.4","spread":null},{"groupId":"OG001","value":"11.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.9","spread":null},{"groupId":"OG001","value":"28.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.0","spread":null},{"groupId":"OG001","value":"26.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":null},{"groupId":"OG001","value":"2.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Pre-specified Local Reactions: Infant Series Dose 2 (4 Months of Age)","description":"Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling and redness present); Mild (0.5 to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\\> 7.0 cm). Participants may be represented in more than 1 category.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.6","spread":null},{"groupId":"OG001","value":"22.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null},{"groupId":"OG001","value":"1.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.9","spread":null},{"groupId":"OG001","value":"15.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.9","spread":null},{"groupId":"OG001","value":"15.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.1","spread":null},{"groupId":"OG001","value":"20.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.1","spread":null},{"groupId":"OG001","value":"17.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"2.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Pre-specified Local Reactions: Infant Series Dose 3 (6 Months of Age)","description":"Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling and redness present); Mild (0.5 to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\\> 7.0 cm). Participants may be represented in more than 1 category.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.4","spread":null},{"groupId":"OG001","value":"17.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.9","spread":null},{"groupId":"OG001","value":"4.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.4","spread":null},{"groupId":"OG001","value":"4.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.9","spread":null},{"groupId":"OG001","value":"13.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.2","spread":null},{"groupId":"OG001","value":"13.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Pre-specified Local Reactions: Toddler Dose (15 Months of Age).","description":"Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling and redness present); Mild (0.5 to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\\> 7.0 cm). Participants may be represented in more than 1 category.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","spread":null},{"groupId":"OG001","value":"22.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":null},{"groupId":"OG001","value":"5.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":null},{"groupId":"OG001","value":"5.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.4","spread":null},{"groupId":"OG001","value":"12.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.8","spread":null},{"groupId":"OG001","value":"12.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Pre-specified Systemic Events: Infant Series Dose 1 (2 Months of Age)","description":"Systemic events (any fever \\>=38 degrees Celsius \\[C\\], decreased appetite, irritability, increased sleep, decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.0","spread":null},{"groupId":"OG001","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null},{"groupId":"OG001","value":"1.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"55.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.0","spread":null},{"groupId":"OG001","value":"70.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.2","spread":null},{"groupId":"OG001","value":"50.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.3","spread":null},{"groupId":"OG001","value":"41.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Pre-specified Systemic Events: Infant Series Dose 2 (4 Months of Age)","description":"Systemic events (any fever \\>=38 degrees C, decreased appetite, irritability, increased sleep, decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.1","spread":null},{"groupId":"OG001","value":"43.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null},{"groupId":"OG001","value":"2.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.7","spread":null},{"groupId":"OG001","value":"56.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.0","spread":null},{"groupId":"OG001","value":"57.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.1","spread":null},{"groupId":"OG001","value":"43.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.3","spread":null},{"groupId":"OG001","value":"32.5","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Pre-specified Systemic Events: Infant Series Dose 3 (6 Months of Age)","description":"Systemic events (any fever \\>=38 degrees C, decreased appetite, irritability, increased sleep, decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.8","spread":null},{"groupId":"OG001","value":"22.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":null},{"groupId":"OG001","value":"9.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"1.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.5","spread":null},{"groupId":"OG001","value":"52.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.6","spread":null},{"groupId":"OG001","value":"47.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.9","spread":null},{"groupId":"OG001","value":"37.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.9","spread":null},{"groupId":"OG001","value":"33.3","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Pre-specified Systemic Events: Toddler Dose (15 Months of Age).","description":"Systemic events (any fever \\>=38 degrees C, decreased appetite, irritability, increased sleep, decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.2","spread":null},{"groupId":"OG001","value":"21.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":null},{"groupId":"OG001","value":"4.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.7","spread":null},{"groupId":"OG001","value":"30.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.7","spread":null},{"groupId":"OG001","value":"27.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":null},{"groupId":"OG001","value":"16.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.2","spread":null},{"groupId":"OG001","value":"23.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":83},"commonTop":["Irritability","Decreased appetite","Fever ≥ 38 degrees C but ≤ 39 degrees C","Increased sleep","Upper respiratory tract infection"]}}}